A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with Neuromyelitis Optica Spectrum Disorders.
Epistemonikos ID: 1767b621d7ddf4a6827fbaff9eca1da89e12ecf7
First added on: May 21, 2024